TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00433420
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02393378
Drug: Namilumab
Normalized name: Namilumab
DrugBank: Namilumab (DB13037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab injection
Study: NCT02393378
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab SC injection
Study: NCT00438009
Drug: Coxsackievirus A21
Normalized name: COXSACKIEVIRUS A21
DrugBank: Gebasaxturev (DB17296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of drug, separated by 48 hours
Study: NCT00354978
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection.
Study: NCT00354978
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle.
Study: NCT00354978
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
Study: NCT03606369
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
Study: NCT03606369
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
Study: NCT02887677
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
Study: NCT01709084
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
Study: NCT01709084
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
Study: NCT01709084
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
Study: NCT04130204
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
Study: NCT01709084
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
Study: NCT03408093
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
Study: NCT04248426
Drug: ATI-2173
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
Study: NCT01453218
Drug: ATeGe-Fresenius
Normalized name: ATG-Fresenius S
DrugBank: ATG-Fresenius S (DB05320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
Study: NCT01764880
Drug: SST0001 (Roneparstat)
Normalized name: Roneparstat
DrugBank: Roneparstat (DB17153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST0001 once daily for 5 or 10 days in a cycle of 28 days.
Study: NCT04585126
Drug: Intermediate cervical block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthesia performed in addition to the general anesthesia
Study: NCT04337463
Drug: ATG-008
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00804908
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: temozolomide capsule administered orally once daily for 5 days every 28 days
Study: NCT00804908
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-888 capsule administered orally twice daily for 7 days every 28 days
Study: NCT04337463
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00501748
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
Study: NCT02515890
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selected subjects received this drug during a portion of the study
Study: NCT02515890
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selected subjects received this drug during a portion of the study
Study: NCT02575638
Drug: CZ48
Normalized name: Cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
Study: NCT01803607
Drug: odanacatib
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: odanacatib 50 mg oral tablet
Study: NCT01444612
Drug: dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
Study: NCT01444612
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
Study: NCT01444612
Drug: fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
Study: NCT01444612
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
Study: NCT02812342
Drug: Tofacitinib ointment
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
Study: NCT02515890
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selected subjects received this drug during a portion of the study
Study: NCT00750061
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks.
Study: NCT01708369
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir 150 mg orally
Study: NCT01708369
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 650 mg orally will be given
Study: NCT00812968
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
Study: NCT01388036
Drug: esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: consecutive infusions of esmolol and normal saline (placebo)
Study: NCT02490098
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT02490098
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study: NCT04337827
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU).
Study: NCT04337827
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU.
Study: NCT00078689
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00136344
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00136344
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00816244
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
Study: NCT03417245
Drug: fitusiran
Normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: by SC injection
Study: NCT03337477
Drug: Sodium Zirconium Cyclosilicate(ZS)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
Study: NCT03337477
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
Study: NCT03337477
Drug: Glucose
Normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose 25g administered IV \<15 minutes before the insulin.
Study: NCT03181932
Drug: Vancomycin inhalation powder
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
Study: NCT03181932
Drug: Vancomycin inhalation powder
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
Study: NCT01281124
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given subcutaneously
Study: NCT00744497
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00744497
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00744497
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03605277
Drug: Asciminib
Normalized name: Asciminib
DrugBank: Asciminib (DB12597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg single dose
Study: NCT02183649
Drug: pentoxyverine citrate
Normalized name: PENTOXYVERINE CITRATE
DrugBank: Pentoxyverine (DB11186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02035891
Drug: colchicine 0.5mg/d
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Study: NCT02038933
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00886626
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide, subcutaneous injection, 10 mcg, twice per day
Study: NCT03819114
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG tablet(s) were administered by mouth in a directly observed manner.
Study: NCT01110902
Drug: Agomelatine (AGO178C)
DrugBank: Agomelatine (DB06594)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00431106
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
Study: NCT00431106
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
Study: NCT00457951
Drug: Open-Label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODSH administered open-label
Study: NCT00457951
Drug: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
Study: NCT00001614
Drug: Chicken type II collagen
Normalized name: collagen type II
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03868657
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
Study: NCT01193244
Drug: Orteronel
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study: NCT03246152
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Repeated intravitreal injections of Bevacizumab monthly
Study: NCT05361005
Drug: BDB-001 injection
Normalized name: BDB 001
DrugBank: BDB-001 (DB16480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT01193244
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study: NCT00638820
Drug: Campath, Busulfan, Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours
Study: NCT04435431
Drug: Mesdopetam
Normalized name: Mesdopetam
DrugBank: Mesdopetam (DB16229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use
Study: NCT01644968
Drug: Cohort 1 anti-OX40
Normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg anti-OX40 on days 1, 3, and 5
Study: NCT01644968
Drug: Cohort 2 anti-OX40
Normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: .4 mg/kg anti-OX40 on days 1, 3, and 5
Study: NCT01644968
Drug: Cohort 3 anti-OX40
Normalized name: anti-OX40 antibody BMS 986178
DrugBank: anti-OX40 antibody BMS 986178 (DB15773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg anti-OX40 on days 1, 3, and 5
Study: NCT03822117
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib administered orally once daily (QD).
Study: NCT00685191
Drug: Salvage antiretroviral therapy including raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initiation of raltegravir-including salvage antiretroviral therapy
Study: NCT01590628
Drug: NiCord
Normalized name: NiCord
DrugBank: Omidubicel (DB17132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
Study: NCT01499498
Drug: Sildenafil and Boceprevir
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg once/800mg three times a day
Study: NCT01006031
Drug: Pegylated interferon alfa-2a and Ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels.
Study: NCT00229931
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
Study: NCT00396357
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00396357
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03854266
Drug: Low dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
Study: NCT03854266
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.